Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, D.C. 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, D.C. 20510

PECETVED.

01 FEB 14 PM 3-59

LOBBYING REPORT

Lobby Disclosure Act of 1995 (Section 5) — All Filers Are Required To Complete This Page

Registrant Name	
	!
Hogan & Harlson L.L.P.	100000000000000000000000000000000000000
2. Address	
Principal Place of Business (if different from line 2) City State	 Zip (or Country)
4. Contact Name Telephone	E-mail (optional) 5. Sepate ID# 1Vickery@HHLAW.com 18422621
7. Client name ☐ Self Glaxo Wellcome Inc.	6. House ID# 36470049
TYPE OF REPORT 8. Year 2000 Midyear (.	January 1-June 30) ☐ OR Year End (July 1-December 31) ☑
9. Check if this filing amends a previously filed version of	f this report 🚨
10. Check if this is a Termination Report □ ⇔ Terminati	ion Date
11. No Lobbying Activity 🗆	
NCOME OR EXPENSES — Complete Either Line 12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was:	13. Organizations
, , , , , , , , , , , , , , , , , , , ,	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 🖾	Less than \$10,000 C
\$10,000 or more	\$10,000 or more
Provide a good faith estimate, rounded to the nearest \$20,000, of all	Expenses (nearest \$20,000)
lobbying related income from the client (including all payments to the registrant by any other catity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check bux to indicate expense accounting method. See instructions for description of options.
	Method A. Reporting amounts using LDA definitions only
	Method B. Reporting amounts under section 6033(b)(8) of the faternal Revenue Code
	Method C. Reporting amounts under section 162(e) of the loternal Revenue Code
Signature Wen Margan Vickery	Date 2/14/01
Printed Name and Title Ann Morean Vickery, Partner	<u> </u>
LD-1 (REV. 6/98)	Page 1 of <u>4</u>
\\D@ - 35526fd - #12641\$9 v	1

OF A		
Registrant Name Hogan & Hartson L.L.P.	Chent Name Glaxo Wellcome Inc.	
LOBBYING ACTIVITY. Select as many codes a engaged in lobbying on behalf of the client during t information as requested. Attach individual page(s)	s necessary to reflect the general issue areas in which the reporting period. Using a separate page for each cas needed.	he registrant ode, provide
15. General issue area code MMM (one p	er page)	
	1 :	
16. Specific lobbying issues	!	
H.R. 4680, Medicare Rx 2000 and other legislation prescription drugs.	regarding Medicare reimbursement for	
17. House(s) of Congress and Federal agencies conta	icted S Check if Notice	
17. Trouster of the Conference and a course affection conference	i CACCO IS ITOISE	
	:	
18. Name of each individual who acted as a lobbyist	in this issue area	
Name	C	1
) Agetic	Covered Official Position (if applicable)	New
Aun Morgan Vickery	Covered Official Position (if applicable)	New
	Covered Official Position (if applicable)	
	Covered Official Position (if applicable)	Ū
	Covered Official Position (if applicable)	a
	Covered Official Position (if applicable)	a a
	Covered Official Position (if applicable)	a a
	Covered Official Position (if applicable)	a a a
	Covered Official Position (if applicable)	0 0 0
Ann Morgan Vickery		0 0 0
Ann Morgan Vickery 19. Interest of each foreign entity in the specific issue		0 0 0
Ann Morgan Vickery 19. Interest of each foreign entity in the specific issue	es listed on line 16 above	0 0 0
Ann Morgan Vickery 19. Interest of each foreign entity in the specific issue Signature Qua Maryan Ui	es listed on line 16 above	0 0 0
Ann Morgan Vickery 19. Interest of each foreign entity in the specific issue Signature Qua Maryan Ui	es listed on line 16 above	0 0 0

Sec. 12.	1	
Registrant Name Hogan & Hartson L.L.P.	Client Name Glaxo Wellcome Inc.	
LOBBYING ACTIVITY. Select as many codes as necengaged in lobbying on behalf of the client during the repinformation as requested. Attach individual page(s) as need to be a select as many codes as need to be a select as need to be a se	porting period. Using a separate page for each of	the registrant rode, provide
15. General issue area code HCR (one per page	2)	
16. Specific lobbying issues		
H.R. 4328, amendments relating to drug pricing.		
17. House(s) of Congress and Federal agencies contacted	Check if None	
18. Name of each individual who acted as a lobbyist in thi	s issue area	
Name	Covered Official Position (if applicable)	New
Donna A. Boswell	!	_
		_
		<u> </u>
	l	Q
		a
		a
		ū
19. Interest of each foreign entity in the specific issues list	and a constitution of the	
	ed on line 16 above	
Signature and Dargan / ick	ed on the 10 above	
Signature <u>Jun Dargan U. Ck</u> Printed Name and Title <u>Ann Morgan Vickery, Partner</u>	: :	
	: :	
	: :	Page 3 of <u>.4</u>

Registrant Name Hogan & Hartson L.L.P.	Client Name Glaxo Wellcome Inc.	
LOBBYING ACTIVITY. Select as many codes as nece engaged in lobbying on behalf of the client during the rep information as requested. Attach individual page(s) as nece	orting period. Using a separate page for ca	
15. General issue area code <u>TRD</u> (one per page)	i !	
16. Specific lobbying issues		
S. 2464 Prescription Drug Fairness Act; S. 2466 A Bill to Require U.S. Trade Representative to price controls.	Enter into Negotiations to Eliminate	
17. House(s) of Congress and Federal agencies contacted	⊠ Check if None	
18. Name of each individual who acted as a lobbyist in this	issue area	
Name	Covered Official Position (if applicable)	New
Name	Covered Official Position (if applicable)	New
Name Warren H. Maruyama	Covered Official Position (if applicable)	0
Warren H. Maruyamu	Covered Official Position (if applicable)	
Warren H. Магцуары		0
Warren H. Maruyamu		0
Warren H. Maruyamu		<u>0</u>
Warren H. Maruyamu		0
Warren H. Maruyama		0 0 0
Warren H. Maruyamu	t on line 16 above	
Warren H. Maruyama 19. Interest of each foreign entity in the specific issues liste Signature Aun Mayan Vi'll	t on line 16 above	